A new method for the separation of androgens from estrogens and for the partition of estriol from the estrone-estradiol fraction: with special reference to the identification and quantitative microdetermination of estrogens by ultraviolet absorption spectrophotometry

It is recognized generally that a qualitative and quantitative knowledge of the excretion pattern of the urinary estrogens is one index to an understanding of the functional activity of the ovary and adrenal cortex. Obviously, such determinations may be useful also in evaluating the normal and abnormal functions of other physiologically related endocrine glands as well as of organs like the liver and kidneys. The clinical applications of these data are self-evident. Various attempts have been made to circumvent the notoriously inaccurate values which have been obtained for the urinary estrogens by a variety of bioassay methods and calorimetric techniques (1, 2). The acknowledged shortcomings of these methods have led us to investigate the application of ultraviolet absorption spectrophotometry to the quantitative determination of the urinary estrogens in an attempt to develop an objective physical method for their accurate determination. It is known that the infra-red portion of the spectrum yields more differentially characteristic curves, but those of the ultraviolet range are more readily obtainable, and consequently better adapted to clinical use. This communication is concerned with studies of the following aspects of the problem: (1) spectrophotometric identification and quantitative micro determination of crystalline estrogens; (2) detection by spectrophotometric assay of gross errors in current methods for extraction and partition of estrogens; (3) studies on the ultraviolet absorption of substances comprising the background material; (4) separation of the phenolic estrogens from the so called neutral steroid fraction; (5) separation of urinary estrogens from other urinary phenolic substances by steam distillation; (6) micro-Girard separation of estrone from estradiol; (7) an essentially new method for the extraction and partition of crystalline estrone, estradiol, and estriol, and their quantitative assay by ultraviolet spectrophotometry

Rapid Responders to Frovatriptan in Acute Migraine Treatment: Results from a Long-Term, Open-Label Study

Background. the Chronic Nature of Migraine and the Reliance on Acute Treatment Constitute the Basis of the Present Long-Term, Open-Label Study. Objectives. First, Assessment of the Tolerability and Safety of Frovatriptan, 2.5-7.5 Mg Taken Orally over 24 Hours, for the Acute Treatment of Migraine, Repeatedly over a 12-Month Period. Second, Assessment of the Efficacy and Tolerability of a Second, Double-Blind Dose of 2.5-Mg Frovatriptan, Compared with Placebo, for Nonresponse at 2 Hours after Treatment of Moderate or Severe Headache with 2.5-Mg Frovatriptan. Results. with Regard to the First Attack Treated, 173 (36%) of the 486 Subjects in the Study Did Not Take a Second Dose at 2 Hours for Nonresponse. at 2 Hours and 4 Hours, These Rapid Responders Experienced a Decrease in Headache Intensity from Moderate or Severe to Mild or No Pain in 84% and 98%, Respectively ( Headache Response ). Six Percent of Them Experienced Recurrence of Moderate or Severe Headache within 24 Hours Following a Response at 4 Hours and 12% Took Rescue Medication. the Response, Measured in Terms of Median Time to Complete Migraine Relief, Was Maintained over 30 Subsequent Migraine Attacks, Treated from Attack 2 Onwards over the Course of 12 Months. Conclusion. Frovatriptan Provides a Remarkably Fast and High Headache Response in a Subgroup of More Than One-Third of Migraineurs, with a Very Low 24-Hour Headache Recurrence and Low Rescue Medication Intake. © 2009 American Academy of Pain Medicine